JLE

Néphrologie & Thérapeutique

MENU

Complications en hémodialyse : focus sur le prurit et les calcifications vasculaires Volume 19, supplement 1, June 2023

Figures


  • Figure 1

  • Figure 2

Tables

Authors
1 Normandie Univ, UNICAEN, CHU de Caen Normandie, néphrologie, Caen, France
2 Normandie université, Unicaen, UFR de médecine, Caen, France
3 Association pour l’utilisation du rein artificiel en région Parisienne (AURA) Nord, Saint-Ouen et Bichat, Saint-Ouen, France
4 Hôpital Necker, service des explorations fonctionnelles rénales, Université Paris Descartes, Paris, France
Correspondance : A. Lanot
Antoine.lanot@gadz.org

Chronic kidney disease-associated pruritus (CKD-aP) is a frequent complication, with an estimated prevalence of 24-37% in patients treated with hemodialysis.

Its pathophysiology is complex and includes four interrelated axes: accumulation of uremic toxins, peripheral neuropathy, an imbalance in the opioid receptors balance, and abnormal activation of immune cells. This symptom which is associated with impaired quality of life is underestimated by caregivers and underreported by patients. Management is not uniformly codified. It includes the use of skin emollients, optimization of dialysis parameters and management of chronic kidney disease complications, and specifically the use of difelikefalin.

Patients treated with hemodialysis have an increased risk of calcifications that can affect the arteries and heart valves. These calcifications are associated with decreased survival and several scores based on radiological examinations have been proposed for screening. Although recommended, this screening is rarely performed in dialysis centers. Prevention and treatment against the development of cardiovascular calcifications are the control of risk factors associated with atherosclerosis, control of phosphatemia, and new therapeutic strategies such as sodium thiosulfate, rheopheresis, vitamin K, magnesium supplementation or SNF-472, a calcium chelator currently in clinical development.